Kailera Therapeutics, Inc.
live · Yahoo FinanceLimited buying: $326.8M bought (counted up to $5.0M); 5 distinct insiders. Holding it back: largest buyer: Kaplan Andrew T. (Director), 41% of the dollars.
AI summary Insiders and major 10% owners purchase shares at the $16 IPO price
Score, not a recommendation.
partial dataAn input is missing, usually the market cap or the price history. A missing input counts as neutral in the score and is never estimated. Market cap is missing; missing inputs count as neutral in the score.
same price, one day All 5 purchases were at $16.00 on 2026-04-20. That pattern also occurs in IPO or conversion subscriptions, which are not open-market conviction buying.
Price and insider purchases
Live chart from Yahoo Finance, loaded through this server; our daily closes when it is unavailable.
Loading price history…
How the score adds up
How each input is counted →| Input | Strength | Points |
|---|---|---|
| $326.8M bought (counted up to $5.0M)The dollars the insiders bought, a purchase reported jointly counted once, counted from $131. Each tenfold adds 12.4 points, up to $5.0M; more adds nothing. The bar is empty at $10.0K and full at $5.0M. | 100% | +57 |
| 5 distinct insidersHow many different insiders bought. Each extra insider adds less than the one before (the points follow the log of the count: 4.3 per doubling). The bar is full at 10 insiders. | 70% | +10 |
| No CEO among the buyersWhether the chief executive is among the buyers: 10.6 points when yes. | 0% | +0 |
| Stock 0% below its 1-year highHow far the stock had fallen from its highest close of the past year, at the close before the buying. Every 10% of fall adds 1.9 points. A fall beyond 30% adds nothing more. The bar is full at a 30% fall. | 0% | +0 |
| 0 days from first to last purchaseDays between the first and the last purchase. Each day takes off 0.11 points: buying close together keeps more. The bar is empty at 60 days. | 100% | +0 |
| Routine or plan purchases: 0% of the dollars | 100% | +0 |
| Largest buyer: Kaplan Andrew T. (Director), 41% of the dollars | 74% | -5 |
| Match scoreA score from 0 to 100 worked out from the dollars bought, the number of insiders, whether a CEO bought, how far the stock had fallen, how spread out the purchases were and how much came from one buyer. Its weights were calibrated on past clusters. It is the default ranking of the lists and it decides which clusters get the AI review. It describes the buying; it is not a forecast. | 62 | |
| AI adjustmentPoints added or taken off by a language model that reads the SEC filings and recent news about the cluster and classifies the buying (for example open market, plan or offering). It can be wrong, it is shown as its own line, and it is never used in past results. | -14 | |
| Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation. | 48 | |
Why are they buying?
AI · ipo_offering · catalyst credible · documentedInsiders and major institutional backers acquired shares directly in connection with the company's initial public offering at the established offering price.
Kailera Therapeutics closed a major upsized $625 million initial public offering priced at $16 per share on April 20, 2026, alongside the conversion of preferred stock into common stock.
Written by an earlier version of the AI review.
Filing references and sources
- A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million (opens in a new tab)
- Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (opens in a new tab)
- A new benchmark for biotech IPOs? Kailera raises $625M (opens in a new tab)
| Date | InsiderAn officer or director of a company, or an owner of more than 10% of its shares. The law requires them to report their trades in the company's stock to the SEC. | Role | Shares | Price | Value | Flags | Filing |
|---|---|---|---|---|---|---|---|
| 2026-04-20 | Kaplan Andrew T. history of Kaplan Andrew T.'s purchases | Director | 8,398,438 | $16.00 | $134.4M | SEC filing for Kaplan Andrew T. (opens in a new tab) | |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC history of BAIN CAPITAL INVESTORS LLC's purchases | 10% owner | 8,398,438 | $16.00 | $134.4M | SEC filing for BAIN CAPITAL INVESTORS LLC (opens in a new tab) | |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC history of Bain Capital Life Sciences Investors, LLC's purchases | 10% owner | 1,562,500 | $16.00 | $25.0M | SEC filing for Bain Capital Life Sciences Investors, LLC (opens in a new tab) | |
| 2026-04-20 | Koppel Adam history of Koppel Adam's purchases | Director | 1,562,500 | $16.00 | $25.0M | SEC filing for Koppel Adam (opens in a new tab) | |
| 2026-04-20 | RTW INVESTMENTS, LP history of RTW INVESTMENTS, LP's purchases | 10% owner | 500,000 | $16.00 | $8.0M | SEC filing for RTW INVESTMENTS, LP (opens in a new tab) | |
| Total | $326.8M | ||||||